432 related articles for article (PubMed ID: 32605658)
1. A ruthenium(II)-curcumin compound modulates NRF2 expression balancing the cancer cell death/survival outcome according to p53 status.
Garufi A; Baldari S; Pettinari R; Gilardini Montani MS; D'Orazi V; Pistritto G; Crispini A; Giorno E; Toietta G; Marchetti F; Cirone M; D'Orazi G
J Exp Clin Cancer Res; 2020 Jun; 39(1):122. PubMed ID: 32605658
[TBL] [Abstract][Full Text] [Related]
2. NRF2 activation in BON‑1 neuroendocrine cancer cells reduces the cytotoxic effects of a novel Ruthenium(II)‑curcumin compound: A pilot study.
Garufi A; Pettinari R; Monteonofrio L; Puliani G; Virdia I; Appetecchia M; Marchetti F; Cirone M; Soddu S; D'Orazi G
Oncol Rep; 2024 Feb; 51(2):. PubMed ID: 38186307
[TBL] [Abstract][Full Text] [Related]
3. Nuclear factor erythroid 2 (NF-E2) p45-related factor 2 interferes with homeodomain-interacting protein kinase 2/p53 activity to impair solid tumors chemosensitivity.
D'Orazi G; Garufi A; Cirone M
IUBMB Life; 2020 Aug; 72(8):1634-1639. PubMed ID: 32593231
[TBL] [Abstract][Full Text] [Related]
4. Metformin induces microRNA-34a to downregulate the Sirt1/Pgc-1α/Nrf2 pathway, leading to increased susceptibility of wild-type p53 cancer cells to oxidative stress and therapeutic agents.
Do MT; Kim HG; Choi JH; Jeong HG
Free Radic Biol Med; 2014 Sep; 74():21-34. PubMed ID: 24970682
[TBL] [Abstract][Full Text] [Related]
5. Nrf2 Regulation by Curcumin: Molecular Aspects for Therapeutic Prospects.
Shahcheraghi SH; Salemi F; Peirovi N; Ayatollahi J; Alam W; Khan H; Saso L
Molecules; 2021 Dec; 27(1):. PubMed ID: 35011412
[TBL] [Abstract][Full Text] [Related]
6. P62/SQSTM1/Keap1/NRF2 Axis Reduces Cancer Cells Death-Sensitivity in Response to Zn(II)-Curcumin Complex.
Garufi A; Giorno E; Gilardini Montani MS; Pistritto G; Crispini A; Cirone M; D'Orazi G
Biomolecules; 2021 Feb; 11(3):. PubMed ID: 33669070
[TBL] [Abstract][Full Text] [Related]
7. Curcumin induces p53-independent inactivation of Nrf2 during oxidative stress-induced apoptosis.
Méndez-García LA; Martínez-Castillo M; Villegas-Sepúlveda N; Orozco L; Córdova EJ
Hum Exp Toxicol; 2019 Aug; 38(8):951-961. PubMed ID: 31018701
[TBL] [Abstract][Full Text] [Related]
8. Long term effect of curcumin in restoration of tumour suppressor p53 and phase-II antioxidant enzymes via activation of Nrf2 signalling and modulation of inflammation in prevention of cancer.
Das L; Vinayak M
PLoS One; 2015; 10(4):e0124000. PubMed ID: 25860911
[TBL] [Abstract][Full Text] [Related]
9. Allele-specific silencing of mutant p53 attenuates dominant-negative and gain-of-function activities.
Iyer SV; Parrales A; Begani P; Narkar A; Adhikari AS; Martinez LA; Iwakuma T
Oncotarget; 2016 Feb; 7(5):5401-15. PubMed ID: 26700961
[TBL] [Abstract][Full Text] [Related]
10. Degradation of mutant p53H175 protein by Zn(II) through autophagy.
Garufi A; Pucci D; D'Orazi V; Cirone M; Bossi G; Avantaggiati ML; D'Orazi G
Cell Death Dis; 2014 May; 5(5):e1271. PubMed ID: 24874727
[TBL] [Abstract][Full Text] [Related]
11. Curcumin inhibits proliferation of breast cancer cells through Nrf2-mediated down-regulation of Fen1 expression.
Chen B; Zhang Y; Wang Y; Rao J; Jiang X; Xu Z
J Steroid Biochem Mol Biol; 2014 Sep; 143():11-8. PubMed ID: 24486718
[TBL] [Abstract][Full Text] [Related]
12. Antiproliferative and Apoptotic Effect of Dendrosomal Curcumin Nanoformulation in P53 Mutant and Wide-Type Cancer Cell Lines.
Montazeri M; Pilehvar-Soltanahmadi Y; Mohaghegh M; Panahi A; Khodi S; Zarghami N; Sadeghizadeh M
Anticancer Agents Med Chem; 2017; 17(5):662-673. PubMed ID: 27604683
[TBL] [Abstract][Full Text] [Related]
13. Mutant p53 confers chemoresistance in non-small cell lung cancer by upregulating Nrf2.
Tung MC; Lin PL; Wang YC; He TY; Lee MC; Yeh SD; Chen CY; Lee H
Oncotarget; 2015 Dec; 6(39):41692-705. PubMed ID: 26497680
[TBL] [Abstract][Full Text] [Related]
14. The Impact of NRF2 Inhibition on Drug-Induced Colon Cancer Cell Death and p53 Activity: A Pilot Study.
Garufi A; Pistritto G; D'Orazi V; Cirone M; D'Orazi G
Biomolecules; 2022 Mar; 12(3):. PubMed ID: 35327653
[TBL] [Abstract][Full Text] [Related]
15. Cancer Cell Growth Is Differentially Affected by Constitutive Activation of NRF2 by KEAP1 Deletion and Pharmacological Activation of NRF2 by the Synthetic Triterpenoid, RTA 405.
Probst BL; McCauley L; Trevino I; Wigley WC; Ferguson DA
PLoS One; 2015; 10(8):e0135257. PubMed ID: 26301506
[TBL] [Abstract][Full Text] [Related]
16. Curcumin-induced apoptosis in ovarian carcinoma cells is p53-independent and involves p38 mitogen-activated protein kinase activation and downregulation of Bcl-2 and survivin expression and Akt signaling.
Watson JL; Greenshields A; Hill R; Hilchie A; Lee PW; Giacomantonio CA; Hoskin DW
Mol Carcinog; 2010 Jan; 49(1):13-24. PubMed ID: 19676105
[TBL] [Abstract][Full Text] [Related]
17. Curcumin mediates selective aggregation of mutant p53 in cancer cells: A promising therapeutic strategy.
Oak S; Karajgikar O; Teni T
Biochem Biophys Res Commun; 2023 Oct; 677():141-148. PubMed ID: 37586212
[TBL] [Abstract][Full Text] [Related]
18. Epigenetics Reactivation of Nrf2 in Prostate TRAMP C1 Cells by Curcumin Analogue FN1.
Li W; Pung D; Su ZY; Guo Y; Zhang C; Yang AY; Zheng X; Du ZY; Zhang K; Kong AN
Chem Res Toxicol; 2016 Apr; 29(4):694-703. PubMed ID: 26991801
[TBL] [Abstract][Full Text] [Related]
19. The curcumin analog HO-3867 selectively kills cancer cells by converting mutant p53 protein to transcriptionally active wildtype p53.
Madan E; Parker TM; Bauer MR; Dhiman A; Pelham CJ; Nagane M; Kuppusamy ML; Holmes M; Holmes TR; Shaik K; Shee K; Kiparoidze S; Smith SD; Park YA; Gomm JJ; Jones LJ; Tomás AR; Cunha AC; Selvendiran K; Hansen LA; Fersht AR; Hideg K; Gogna R; Kuppusamy P
J Biol Chem; 2018 Mar; 293(12):4262-4276. PubMed ID: 29382728
[TBL] [Abstract][Full Text] [Related]
20. Curcumin Modulates Glycolytic Metabolism and Inflammatory Cytokines via Nrf 2 in Dalton's Lymphoma Ascites Cells In Vivo.
Das L; Vinayak M
Anticancer Agents Med Chem; 2018; 18(12):1779-1791. PubMed ID: 29866021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
